Skip to Content
Merck
  • The HicA toxin from Burkholderia pseudomallei has a role in persister cell formation.

The HicA toxin from Burkholderia pseudomallei has a role in persister cell formation.

The Biochemical journal (2014-02-08)
Aaron Butt, Victoria A Higman, Christopher Williams, Matthew P Crump, Claudia M Hemsley, Nicholas Harmer, Richard W Titball
ABSTRACT

TA (toxin-antitoxin) systems are widely distributed amongst bacteria and are associated with the formation of antibiotic tolerant (persister) cells that may have involvement in chronic and recurrent disease. We show that overexpression of the Burkholderia pseudomallei HicA toxin causes growth arrest and increases the number of persister cells tolerant to ciprofloxacin or ceftazidime. Furthermore, our data show that persistence towards ciprofloxacin or ceftazidime can be differentially modulated depending on the level of induction of HicA expression. Deleting the hicAB locus from B. pseudomallei K96243 significantly reduced persister cell frequencies following exposure to ciprofloxacin, but not ceftazidime. The structure of HicA(H24A) was solved by NMR and forms a dsRBD-like (dsRNA-binding domain-like) fold, composed of a triple-stranded β-sheet, with two helices packed against one face. The surface of the protein is highly positively charged indicative of an RNA-binding protein and His24 and Gly22 were functionality important residues. This is the first study demonstrating a role for the HicAB system in bacterial persistence and the first structure of a HicA protein that has been experimentally characterized.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ciprofloxacin HCl, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ceftazidime pentahydrate, United States Pharmacopeia (USP) Reference Standard
Ceftazidime, European Pharmacopoeia (EP) Reference Standard
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Supelco
Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
USP
Ciprofloxacin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Ceftazidime for peak identification, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin hydrochloride for peak identification, European Pharmacopoeia (EP) Reference Standard